HOME >> BIOLOGY >> NEWS
Tomato packs more cancer-fighting punch

WEST LAFAYETTE, Ind. Forget the attack of the killer tomato, this is the attack of the healthy tomato: A team of scientists has developed a tomato that contains as much as three and a half time more of the cancer-fighting antioxidant lycopene.

It turns out that the antioxidant-rich tomato was a happy accident.

Scientists at Purdue University and the U.S. Department of Agriculture's Agricultural Research Service were working to develop tomatoes for food processing that were of higher quality and would ripen later.

They accomplished that, but in the process they discovered that the new tomatoes also had significantly more of the antioxidant than conventional tomatoes.

"We were quite pleasantly surprised to find the increase in lycopene," says Avtar Handa (pronounced "Honda"), professor of horticulture at Purdue.

Although increasing the nutritional value of foods is the goal of so-called second-generation biotechnology products, there have been few success stories.

"This is one of the first examples of increasing the nutritional value of food through biotechnology," Handa says. "In fact, it may be the first example of using biotechnology to increase the nutritional value of a fruit."

Co-discoverer Autar Mattoo, who heads the USDA Vegetable Laboratory, says the increase in lycopene occurred naturally in the genetically modified tomatoes. "The pattern for the accumulation was the same as in the control tomatoes," he says. "The lycopene levels increased two to 3.5 times compared to the non-engineered tomatoes."

The research was announced this week in the June issue of Nature Biotechnology.

A separate article on the research in Nature Biotechnology noted, "The findings remind us that in the 'rational' and quantitatively driven post-genomic era, serendipity still has a large part to play."

A U.S. patent application has been filed on behalf of the joint owners USD
'"/>

Contact: Steve Tally
tally@purdue.edu
765-494-9809
Purdue University
18-Jun-2002


Page: 1 2 3 4

Related biology news :

1. Tomato ripening gene could make store tomatoes tastier
2. Newly Identified Tomato Gene Appears Key To Fruit Softening
3. Molecular motor packs DNA into viruses at greater than champagne pressures, researchers report
4. Uncovering structure of cellular switch could aid design of cancer-fighting drugs
5. Researchers discover new vein of cancer-fighting agents
6. New compound could give some types of cancer the one-two punch
7. Avastin-Tarceva combo provides one-two punch against lung cancer
8. Study suggests double punch could more efficiently kill viruses
9. As bodies age, disease-fighting cells lose punch
10. Legumes found to contain starch carrying a fiber-like punch
11. One-two punch knocks out fly genes

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Tomato packs more cancer fighting punch

(Date:3/23/2015)... LOS ANGELES , March 23, 2015  In ... in Federal fraud case conviction losses. This figure accounts ... fraud, which, according to The Nilson Report, exceeds $11 ... an investigative tool after a crime has occurred. Investor ... Agent and polygraph expert Joe Paolella partnered ...
(Date:3/20/2015)... , Mar. 19, 2015 Research and Markets ... "Iris Biometrics - Global Strategic Business Report" report ... markets for Iris Biometrics in US$ Thousands. The report provides ... , Japan , Europe ... , and Latin America . ...
(Date:3/17/2015)...  MecklerMedia Corporation (OTCQX: MECK) announced its ... ever held in New York City ... 2015 at the Javits Convention Center. ... Acorn Product Development; Axis NJ; c-Link Systems; CoroWare; ... NewBotic Corporation; Neya Systems LLC; Reliabotics; RoboKind; RocketFarm ...
Breaking Biology News(10 mins):Polygraph Test Now Used to Protect Investors From Fraud 2Polygraph Test Now Used to Protect Investors From Fraud 3Iris Biometrics - Global Strategic Business Report 2015: System & Network Access Control - A Robust Market Opportunity in the Offing 2Iris Biometrics - Global Strategic Business Report 2015: System & Network Access Control - A Robust Market Opportunity in the Offing 3Iris Biometrics - Global Strategic Business Report 2015: System & Network Access Control - A Robust Market Opportunity in the Offing 4Iris Biometrics - Global Strategic Business Report 2015: System & Network Access Control - A Robust Market Opportunity in the Offing 5MecklerMedia's RoboUniverse New York Announces Sponsors and Exhibitors, May 11-13, 2015 2
(Date:3/30/2015)... 2015 CASI Pharmaceuticals, Inc. (Nasdaq: CASI ... and commercialization of innovative therapeutics addressing cancer and other ... commercial focus on China , announced ... has approved the Company,s application to conduct a Phase ... (OCCC) patients for its proprietary drug candidate ENMD-2076.  ...
(Date:3/30/2015)... CARDIFF, UK, and BELLINGHAM, Washington, USA (PRWEB) March 29, ... energy projects in Europe and the United States and ... programme highlights planned for SPIE Optics + Optoelectronics ... will feature over 700 technical presentations in 17 conferences ... international society for optics and photonics , the event ...
(Date:3/30/2015)... MADISON, Wis. , March 30, 2015  FUJIFILM ... ("Fujifilm") and Cellular Dynamics International, Inc. (CEO: Robert ... leading developer and manufacturer of fully functioning human cells ... the two companies have entered into a definitive agreement ... offer to be followed by a second step merger. ...
(Date:3/29/2015)... March 29, 2015 As a symbol ... required by our pharmaceutical manufacturing clients, Whitehouse Laboratories is ... of the Berkenstock Race Team for the 2015 race ... only speed, but a strong sense of precision and ... lead to success in the quality control testing laboratory. ...
Breaking Biology Technology:CASI Pharmaceuticals Receives Approval From CFDA For Phase 2 Clinical Trial In China With ENMD-2076 For Ovarian Clear Cell Carcinoma 2CASI Pharmaceuticals Receives Approval From CFDA For Phase 2 Clinical Trial In China With ENMD-2076 For Ovarian Clear Cell Carcinoma 3CASI Pharmaceuticals Receives Approval From CFDA For Phase 2 Clinical Trial In China With ENMD-2076 For Ovarian Clear Cell Carcinoma 4CASI Pharmaceuticals Receives Approval From CFDA For Phase 2 Clinical Trial In China With ENMD-2076 For Ovarian Clear Cell Carcinoma 5Laser Energy Advances Among Reports Set for SPIE Optics + Optoelectronics 2Laser Energy Advances Among Reports Set for SPIE Optics + Optoelectronics 3Fujifilm Holdings to Acquire Cellular Dynamics International, Inc. 2Fujifilm Holdings to Acquire Cellular Dynamics International, Inc. 3Fujifilm Holdings to Acquire Cellular Dynamics International, Inc. 4Fujifilm Holdings to Acquire Cellular Dynamics International, Inc. 5Fujifilm Holdings to Acquire Cellular Dynamics International, Inc. 6Fujifilm Holdings to Acquire Cellular Dynamics International, Inc. 7Fujifilm Holdings to Acquire Cellular Dynamics International, Inc. 8Whitehouse Laboratories Reaffirms Commitment to Speedy Results – Renews Sponsorship of Berkenstock Racing Team 2
Cached News: